Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

NCT03065816 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG: Z0063
DRUG: Gaviscon

Sponsor

Sanofi